Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pem

Trial Details

NCT ID

NCT05269381

Phase

PHASE1 / PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Cyclophosphamide
Neoantigen Peptide Vaccine
Pembrolizumab
Sargramostim
Biospecimen Collection
Biopsy

Locations (sample)

Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

PHASE I PRE-REGISTRATION, ALL:
Willing to provide tissue specimens per protocol
NOTE: includes fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing. Patients who had tumor sequencing under c…
Measurable disease as defined by RECIST (version 1.1) criteria or non-measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →